JO3489B1 - مركبات تراي أزولوبيريميدين واستخداماتها - Google Patents

مركبات تراي أزولوبيريميدين واستخداماتها

Info

Publication number
JO3489B1
JO3489B1 JOP/2015/0331A JOP20150331A JO3489B1 JO 3489 B1 JO3489 B1 JO 3489B1 JO P20150331 A JOP20150331 A JO P20150331A JO 3489 B1 JO3489 B1 JO 3489B1
Authority
JO
Jordan
Prior art keywords
triazolopyrimidines
shireen
image002
appdata
prc2
Prior art date
Application number
JOP/2015/0331A
Other languages
English (en)
Inventor
Sendzik Martin
Mi Yuan
Huang Ying
Justin Gu Xiang-Ju
Man Chan Ho
Yu Zhengtian
Yue Ji (Jeff) Zhang
Zhao Kehao
Sun Yongfeng
Zhang Hailong
Li Ling
Zhang Man
Zhang Qiong
Qi Wei
Wang Long
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3489B1 publication Critical patent/JO3489B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركب من الصيغة (I)، أو ملح مقبول صيدلانيا منه، والذي اتضح أنه مفيد في علاج مرض أو اضطراب ناتج عن PRC2: حيث R1، وR2، وR3، وR4، وR5، وn هي كما هي محددة هن <img src="file:///C:/Users/shireen.s/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />
JOP/2015/0331A 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها JO3489B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23

Publications (1)

Publication Number Publication Date
JO3489B1 true JO3489B1 (ar) 2020-07-05

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0331A JO3489B1 (ar) 2014-12-23 2015-12-22 مركبات تراي أزولوبيريميدين واستخداماتها

Country Status (40)

Country Link
US (5) US9580437B2 (ar)
EP (1) EP3237418B1 (ar)
JP (1) JP6736559B2 (ar)
KR (1) KR102534028B1 (ar)
CN (1) CN107108637B (ar)
AU (1) AU2015370524B2 (ar)
BR (1) BR112017010354B8 (ar)
CA (1) CA2969090C (ar)
CL (1) CL2017001572A1 (ar)
CO (1) CO2017005992A2 (ar)
CR (1) CR20170285A (ar)
CY (1) CY1121901T1 (ar)
DK (1) DK3237418T3 (ar)
DO (1) DOP2017000149A (ar)
EA (1) EA032416B1 (ar)
EC (1) ECSP17047153A (ar)
ES (1) ES2722048T3 (ar)
GT (1) GT201700146A (ar)
HR (1) HRP20190805T1 (ar)
HU (1) HUE043060T2 (ar)
IL (1) IL252135B (ar)
JO (1) JO3489B1 (ar)
LT (1) LT3237418T (ar)
ME (1) ME03385B (ar)
MX (1) MX375970B (ar)
MY (1) MY186837A (ar)
NZ (1) NZ731664A (ar)
PE (1) PE20171307A1 (ar)
PH (1) PH12017501016B1 (ar)
PL (1) PL3237418T3 (ar)
PT (1) PT3237418T (ar)
RS (1) RS58679B1 (ar)
SG (1) SG11201703880VA (ar)
SI (1) SI3237418T1 (ar)
SV (1) SV2017005472A (ar)
TN (1) TN2017000204A1 (ar)
TW (1) TWI694076B (ar)
UA (1) UA120945C2 (ar)
UY (1) UY36462A (ar)
WO (1) WO2016103155A1 (ar)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032416B1 (ru) * 2014-12-23 2019-05-31 Новартис Аг Соединения триазолопиримидина и их применения
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
EP3472168B1 (en) * 2016-06-20 2024-01-10 Novartis AG Crystalline forms of triazolopyrimidine compound
WO2017221092A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
KR102598895B1 (ko) 2016-07-12 2023-11-07 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
RU2764655C2 (ru) * 2017-03-16 2022-01-19 Цзянсу Хэнжуй Медицин Ко., Лтд. ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
TW201927791A (zh) * 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
US11591312B2 (en) 2018-01-23 2023-02-28 Basf Se Halogenation of pyridine derivatives
NZ766447A (en) * 2018-01-31 2021-12-24 Mirati Therapeutics Inc Prc2 inhibitors
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
CA3120791A1 (en) * 2018-11-30 2020-06-04 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
TWI845638B (zh) * 2019-03-15 2024-06-21 美商弗爾康醫療公司 Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物
WO2020204024A1 (ja) * 2019-04-03 2020-10-08 テラ・ストーン株式会社 チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法
WO2020219448A1 (en) * 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CN113874377A (zh) 2019-05-13 2021-12-31 埃科莱布美国股份有限公司 作为铜腐蚀抑制剂的1,2,4-三唑并[1,5-a]嘧啶衍生物
JP7541538B2 (ja) * 2019-06-05 2024-08-28 ミラティ セラピューティクス，インク． 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体
EP3980021A4 (en) * 2019-06-05 2023-06-14 Atnx Spv, Llc METHODS OF TREATMENT AND/OR PREVENTION OF PSORIASIS
EP3999510A1 (en) 2019-07-16 2022-05-25 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof
CN112409385B (zh) * 2019-08-22 2024-08-13 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
CN114746414B (zh) * 2019-09-26 2024-10-18 诺华公司 氮杂-喹啉化合物及其用途
WO2021083380A1 (zh) * 2019-11-01 2021-05-06 上海科技大学 Eed抑制剂及其制备方法和用途
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
CN113636993B (zh) * 2020-05-11 2022-08-19 苏州亚盛药业有限公司 (5-氟-2,3-二氢苯并呋喃-4-基)甲胺或其盐的制备方法及其中间体
US20230293529A1 (en) * 2020-05-28 2023-09-21 Novartis Ag Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN115703799B (zh) * 2021-08-11 2024-11-08 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
US6894055B2 (en) * 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2003076424A1 (en) 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) * 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
WO2005118796A2 (en) 2004-06-01 2005-12-15 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
ES2481402T3 (es) 2005-07-21 2014-07-30 Ardea Biosciences, Inc. Inhibidores de N-(arilamino)sulfonamida de MEK
JO2660B1 (ar) 2006-01-20 2012-06-17 نوفارتيس ايه جي مثبطات الكاينيز Pi-3 وطرق استخدامها
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
CA2673784A1 (en) 2006-12-27 2008-07-10 Usc Stevens-University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
ES2593279T3 (es) 2007-08-29 2016-12-07 Methylgene Inc. Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
EA023788B1 (ru) * 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
EP2953941B1 (en) 2013-02-11 2017-04-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR102587175B1 (ko) 2012-03-12 2023-10-06 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
CN105189506A (zh) 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
WO2014100080A1 (en) 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
RU2731051C2 (ru) 2014-11-14 2020-08-28 Басф Се Бензилпропаргиловые простые эфиры в качестве ингибиторов нитрификации
ES2668688T3 (es) 2014-12-16 2018-05-21 Omya International Ag Carbonato de calcio para protección vegetal
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EA032416B1 (ru) * 2014-12-23 2019-05-31 Новартис Аг Соединения триазолопиримидина и их применения
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences

Also Published As

Publication number Publication date
PH12017501016A1 (en) 2017-12-11
KR102534028B1 (ko) 2023-05-19
CO2017005992A2 (es) 2017-10-20
DK3237418T3 (da) 2019-05-13
PT3237418T (pt) 2019-05-23
ME03385B (me) 2020-01-20
BR112017010354A2 (pt) 2017-12-26
JP2018500342A (ja) 2018-01-11
AU2015370524A1 (en) 2017-06-01
TW201629065A (zh) 2016-08-16
EP3237418A1 (en) 2017-11-01
SG11201703880VA (en) 2017-07-28
LT3237418T (lt) 2019-05-10
CY1121901T1 (el) 2020-10-14
CL2017001572A1 (es) 2018-01-12
NZ731664A (en) 2024-02-23
EA201791420A1 (ru) 2017-10-31
ECSP17047153A (es) 2019-02-28
RS58679B1 (sr) 2019-06-28
SV2017005472A (es) 2018-06-12
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
US11931363B2 (en) 2024-03-19
SI3237418T1 (sl) 2019-06-28
PH12017501016B1 (en) 2017-12-11
CN107108637A (zh) 2017-08-29
US9580437B2 (en) 2017-02-28
CA2969090C (en) 2023-05-02
UA120945C2 (uk) 2020-03-10
HRP20190805T1 (hr) 2019-06-28
PL3237418T3 (pl) 2019-07-31
IL252135B (en) 2020-06-30
MY186837A (en) 2021-08-25
MX375970B (es) 2025-03-06
CR20170285A (es) 2017-08-21
US11207325B2 (en) 2021-12-28
BR112017010354B1 (pt) 2022-09-20
BR112017010354B8 (pt) 2022-10-18
UY36462A (es) 2016-07-29
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
TN2017000204A1 (en) 2018-10-19
JP6736559B2 (ja) 2020-08-05
US20160176882A1 (en) 2016-06-23
US20230033320A1 (en) 2023-02-02
CN107108637B (zh) 2019-10-29
GT201700146A (es) 2019-06-12
ES2722048T3 (es) 2019-08-07
AU2015370524B2 (en) 2018-11-01
MX2017008529A (es) 2017-10-25
KR20170095882A (ko) 2017-08-23
US20200323859A1 (en) 2020-10-15
US20170348312A1 (en) 2017-12-07
HUE043060T2 (hu) 2019-07-29
IL252135A0 (en) 2017-07-31
DOP2017000149A (es) 2017-07-15
EP3237418B1 (en) 2019-01-30
WO2016103155A1 (en) 2016-06-30
EA032416B1 (ru) 2019-05-31
CA2969090A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
JO3489B1 (ar) مركبات تراي أزولوبيريميدين واستخداماتها
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201692219A1 (ru) Способы получения противовирусных соединений
MX391812B (es) Agonista fxr derivado de esteroides.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX392779B (es) Anticuerpos anti-cd27
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201690478A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТРИАЗОЛ[4,5-d]ПИРИМИДИНА
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
JO3579B1 (ar) مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
MA38404A1 (fr) Nouveaux dérivés de pyridine
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
PH12017500095A1 (en) Imidazopyridazine compounds
MY194307A (en) Pyridone derivative having tetrahydropyranylmethyl group
EA201890632A1 (ru) Хиральные фосфорамидимидаты и их производные
EA201992832A1 (ru) Подкожное введение adamts13
EA201692550A1 (ru) Соединения, содержащие систему 1,1&#39;,2,5&#39;-тетрагидроспиро[индол-3,2&#39;-пиррол]-2,5&#39;-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2